Exelixis company profile

EXEL · NASDAQ · USD

Compare Exelixis
$68.25Change from previous close: −1.09%Absolute change: −$0.75

Close · November 16, 2026

Company profile

Exelixis has 1,077 employees and is headquartered in Alameda, United States.

Incorporated in 1994 and based in Alameda, California, Exelixis offers medicines for cancers that are difficult to treat. Its marketed products include CABOMETYX, used for advanced renal cell carcinoma after prior anti-angiogenic therapy, COMETRIQ for progressive and metastatic medullary thyroid cancer, and COTELLIC, used in combination for certain forms of advanced melanoma. MINNEBRO is offered for hypertension in Japan. Its pipeline includes zanzalintinib and several antibody-drug conjugates, and the company has research collaborations and license agreements with Takeda, Roche, Genentech, Bristol-Myers Squibb and Daiichi Sankyo.

In the fiscal year ended January 2, 2026, revenue was $2.3 billion, up 7.0% from the prior year, and net income reached $782.6 million. Revenue by region was 92.3% from the United States, 6.6% from Europe and 1.1% from Japan. The company had 1,077 employees.

Company facts

Industry
Biotechnology
Headquarters
1851 Harbor Bay Parkway, 94502, Alameda
Employees
1,077
Chief executive
Michael Morrissey
Founded
1994
Fiscal year
January - December
Listing
EXEL · NASDAQ
Currency
USD
ISIN
US30161Q1040

Exelixis and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
ExelixisEXELUnited States$16.84B1,07740.2%20.7
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1
Jazz PharmaceuticalsJAZZUnited States$15.5B2,89027.4%71.5
BridgeBio PharmaBBIOUnited States$15.25B1,081-37.3%—
BioNTechBNTXUnited States$21.22B7,807-55.4%—
Alnylam PharmaceuticalsALNYUnited States$22.11B2,50019.5%8.34

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Exelixis with its competitors